These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12014351)

  • 1. Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a.
    Lamb MW; Martin NE
    Ann Pharmacother; 2002 May; 36(5):933-5. PubMed ID: 12014351
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hepatitis C infection. Overweight virus carriers are more difficult to cure].
    MMW Fortschr Med; 2004 Mar; 146(13):58. PubMed ID: 15219135
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of peginterferons.
    Zeuzem S; Welsch C; Herrmann E
    Semin Liver Dis; 2003; 23 Suppl 1():23-8. PubMed ID: 12934165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
    Fried MW; Hadziyannis SJ
    Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
    Ferenci P
    Int J Clin Pract; 2003 Sep; 57(7):610-5. PubMed ID: 14529063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C.
    Bruno R; Sacchi P; Maiocchi L; Zocchetti C; Ciappina V; Patruno S; Filice G
    Antivir Ther; 2005; 10(2):201-5. PubMed ID: 15865213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferons.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(2):87-99. PubMed ID: 12120178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful therapy with pegylated interferon alfa-2a. Hepatitis C patients remain virus-free].
    MMW Fortschr Med; 2003 Sep; 145(35-36):56. PubMed ID: 14584218
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C.
    van der Eijk AA; Vrolijk JM; Haagmans BL
    N Engl J Med; 2006 Mar; 354(12):1323-4. PubMed ID: 16554542
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.
    Brennan BJ; Lemenuel-Diot A; Snoeck E; McKenna M; Solsky J; Wat C; Mallalieu NL
    Br J Clin Pharmacol; 2016 Apr; 81(4):658-66. PubMed ID: 26529640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
    J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
    Forestier N; Reesink HW; Weegink CJ; McNair L; Kieffer TL; Chu HM; Purdy S; Jansen PL; Zeuzem S
    Hepatology; 2007 Sep; 46(3):640-8. PubMed ID: 17879366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
    J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.
    Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.
    Rotman Y; Katz L; Cohen M; Cohen-Ezra O; Manhaim V; Braun M; Ben-Ari Z; Tur-Kaspa R
    J Viral Hepat; 2009 May; 16(5):340-5. PubMed ID: 19220735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of long-acting interferon (peginterferon)].
    Kondo Y; Tateishi R; Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):515-8. PubMed ID: 15359853
    [No Abstract]   [Full Text] [Related]  

  • 18. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
    Reddy KR; Shiffman ML; Rodriguez-Torres M; Cheinquer H; Abdurakhmanov D; Bakulin I; Morozov V; Silva GF; Geyvandova N; Stanciu C; Rabbia M; McKenna M; Thommes JA; Harrison SA;
    Gastroenterology; 2010 Dec; 139(6):1972-83. PubMed ID: 20816836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pegylated interferons: pharmacological basis].
    Macquin-Mavier I; Hezode C; Dhumeaux D
    Gastroenterol Clin Biol; 2002; 26(8-9):742-7. PubMed ID: 12434079
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Malone DC; Tran TT; Poordad FF
    J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.